

UCB to Acquire Neurona Therapeutics

*Committed to Improving Lives of
People Living with Severe
Diseases*

April 2026



Inspired by **patients.**
Driven by **science.**



Disclaimer & Safe Harbor

This document contains forward-looking statements, including, without limitation, statements containing the words “potential”, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will”, “continue” and similar expressions. These forward-looking statements are based on current plans, estimates and beliefs of management. All statements, other than statements of historical facts, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, arbitration, political, regulatory or clinical results or practices and other such estimates and results. By their nature, such forward-looking statements are not guaranteeing future performance and are subject to known and unknown risks, uncertainties, and assumptions which might cause the actual results, financial condition, performance or achievements of UCB, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements contained in this document.

Important factors that could result in such differences include but are not limited to: global spread and impacts of wars, pandemics and terrorism, the general geopolitical environment, climate change, changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, safety, quality, data integrity or manufacturing issues, supply chain disruption and business continuity risks; potential or actual data security and data privacy breaches, or disruptions of UCB’s information technology systems, product liability claims, challenges to patent protection for products or product candidates, competition from other products including biosimilars or disruptive technologies/business models, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in laws and/or rules pertaining to tax and duties or the administration of such laws and/or rules, and hiring, retention and compliance of employees. There is no guarantee that new product candidates will be discovered or identified in the pipeline, or that new indications for existing products will be developed and approved. Movement from concept to commercial product is uncertain; preclinical results do not guarantee safety and efficacy of product candidates in humans. So far, the complexity of the human body cannot be reproduced in computer models, cell culture systems or animal models. The length of the timing to complete clinical trials and to get regulatory approval for product marketing has varied in the past and UCB expects similar unpredictability going forward. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to disputes between the partners or may prove to be not as safe, effective or commercially successful as UCB may have believed at the start of such partnership. UCB’s efforts to acquire other products or companies and to integrate the operations of such acquired companies may not be as successful as UCB may have believed at the moment of acquisition. Also, UCB or others could discover safety, side effects or manufacturing problems with its products and/or devices after they are marketed. The discovery of significant problems with a product similar to one of UCB’s products that implicate an entire class of products may have a material adverse effect on sales of the entire class of affected products. Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment, including pricing pressure, political and public scrutiny, customer and prescriber patterns or practices, and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement activities and outcomes. Finally, a breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of UCB’s data and systems.

Given these uncertainties, the public is cautioned not to place any undue reliance on such forward-looking statements. These forward-looking statements are made only as of the date of this document, and do not reflect any potential impacts from the evolving event or risk as mentioned above as well as any other adversity, unless indicated otherwise. The company continues to follow the development diligently to assess the financial significance of these events, as the case may be, to UCB.

UCB expressly disclaims any obligation to update any forward-looking statements in this document, either to confirm the actual results or to report or reflect any change in its forward-looking statements with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless such statement is required pursuant to applicable laws and regulations.

UCB's Patient Value Strategy

Improving Outcomes Through Disease Modification

UCB's Portfolio of Epilepsy Solutions

Keppra[®]
levetiracetam

VIMPAT[®]
lacosamide

BRIVIACT[®]
(brivaracetam)

Nayzilam[®]
(midazolam) nasal spray

Fintepla[®]
(fenfluramine)

UCB's ambition in epilepsy

Symptom Control



Manage Symptoms

Short-Term Relief

Disease-Modifying Therapies



Target the Cause

Long-Term Improvement

TRANSITION

Decades-long commitment to epilepsy, anchored in deep scientific and clinical expertise

Broad and differentiated portfolio addressing multiple seizure types and patient needs

Strong focus on patients with **high unmet need**, including drug-refractory epilepsies


Ambition to advance disease-modifying approaches beyond symptomatic seizure control, building on our leadership as innovator in epilepsy

Drug Resistant Focal Epilepsy- a Significant Unmet Medical Need

A debilitating disease severely impacting quality of life



Mesial temporal lobe epilepsy (MTLE) is the most common type of focal epilepsy



Around 600K drug resistant focal epilepsy patients in US, UK, JP & EU4*



MTLE originates in the temporal lobe and impacts cognition, especially memory



Current standard of Care: Resective surgery and therapeutic neurostimulation

Current Standard of Care

RESECTIVE SURGERY/ LASER ABLATION



Focal resection or laser ablation can cause irreversible verbal memory impairment, cognitive deficits, and personality changes.

THERAPEUTIC NEUROSTIMULATION



Implanted neurostimulation is an option, but clinical benefit is usually incremental, with many patients continuing to experience significant seizure burden

Potential First-in-class Transformative Cell Therapies

For Chronic Neurological Disorders

Neurona Therapeutics - Company description



HQ: San Francisco, CA



Founded in 2008



~100 employees



Private Company

Lead asset description

NRTX-1001, a **potential first-in-class** GABAergic interneuron cell therapy with **minimally invasive** delivery procedure

Designed to **restore neural circuit balance** with potential for single-administration and long-lasting benefit


Advancing through **Phase I/II trials for drug-resistant mesial temporal lobe epilepsy**, with potential expansion into other focal epilepsies

Regulatory momentum with **FDA RMAT designation** (June 2024) and **EMA PRIME designation** (October 2025), supporting accelerated development and regulatory approval

Pivotal Phase 3 trial planned to be initiated in **2026**

Accelerating Future Growth

Strategic Rationale for Acquiring Neurona Therapeutics



Fully aligned with UCB's **long term growth priorities**. Neurona Therapeutics is highly complementary and builds on our **30-year heritage and leadership as an innovator in epilepsy**



It **accelerates** our entry into **next generation disease-modifying therapies** - regenerative medicines, taking us to the next level of our **patient value strategy**- differentiated medicines with the potential to go beyond treating symptoms to disease modification



NTRX-001 an allogenic **potential first-in-class cell therapy** provides the possibility for patients to be seizure free with a **single dose without the limitations of current standard of care**, resective surgery, laser ablation or therapeutic neurostimulation



Built on a **novel regenerative cell therapy platform**, enabling potential long-term repair of dysfunctional neural networks **across multiple neurological disorders**

Compelling Value Proposition for All Stakeholders

Terms Upon Closure of the Transaction

Consideration

- Upfront of \$650mm in cash upon closing
- Milestone of \$200mm in cash upon receipt of FDA approval
- Milestone of up to \$300mm in commercial milestones

Timing

- Transaction approved by the Boards of both companies
- Closing subject to antitrust clearances and other customary closing conditions
- Closing expected by end of Q2 2026

Financial impact

- 2026 Revenue guidance remains unchanged. 2026 underlying profitability, as measured by adjusted EBITDA, is now expected to grow in a high single-digit to mid-teens percentage range at constant exchange rates (CER)*

** These expectations exclude the potential impact of U.S. tariffs and any implications related to a Most Favoured Nation (MFN) pricing arrangement, as no final outcomes have been determined at this stage.*



For further information:

Investor Relations

investor-relations@ucb.com

Corporate Communications, Media Relations

laurent.schots@ucb.com